MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
October 30 2023 - 7:00AM
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic, off-the-shelf, invariant
natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases, today announced that the company will
release its third quarter 2023 financial results via press release
before the market opens on Thursday, Nov. 9, 2023.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical
company pioneering the discovery, development, and
commercialization of allogeneic invariant natural killer T (iNKT)
cell therapies to treat cancer and other immune-mediated diseases.
MiNK is advancing a pipeline of both native and next generation
engineered iNKT programs, with a platform designed to facilitate
scalable and reproducible manufacturing for off-the-shelf delivery.
The company is headquartered in New York, NY. For more
information, visit https://minktherapeutics.com/ or
@MiNK_iNKT. Information that may be important to investors will be
routinely posted on our website and social media channels.
Investor
Contact917-362-1370investor@minktherapeutics.com
Media
Contact781-674-4428communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
From Apr 2024 to May 2024
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
From May 2023 to May 2024